Mirati Therapeutics, Inc.’s KRAS-inhibitor candidate adagrasib has succeeded in a registrational-enabling Phase II study in non-small cell lung cancer (NSCLC) but experts were skeptical about the drug’s potential to best Amgen, Inc.’s already marketed competitor, Lumakras (sotorasib).
The new data were released ahead of the American Society of Clinical Oncology meeting in Chicago next month from the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?